Moderna submitted an emergency use authorization request Sept. 23 for its bivalent, omicron-targeted boosters for 12- to 17-year-olds and 6- to 11-year-olds, the company tweeted. Pfizer followed three days later with its application for 5- to 11-year-olds.
Currently, Moderna’s updated booster shot is authorized for adults 18 and older, and Pfizer’s option is authorized for ages 12 and up. As of Sept. 21, 4.4 million people — or about 1.5 percent of the U.S. population that’s eligible for the new booster — have received the updated booster.
In another tweet, Moderna said it plans to seek authorization for its omicron booster for children as young as 6 months old by the end of 2022. Pfizer did not give a projected date for its tweaked booster for the youngest population, but the drugmaker has a phase 1/2/3 clinical study underway testing it.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
